Efficacy of ustekinumab, an il-12/23 monoclonal antibody, in psoriatic arthritis patients with baseline c-reactive protein >= 0.4 vs. < 0.4 Mg/dl: Post hoc analysis of a phase 2, randomized, double-blind, placebo-controlled trial

Authors
Category Primary study
JournalZeitschrift fur Rheumatologie
Year 2010
This article has no abstract
Epistemonikos ID: 3df67c2f8364fa4b39b41f2de60602e3a8f77342
First added on: Mar 01, 2025